BeiGene Ltd ADR [BGNE] stock is trading at $160.26, up 3.33%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The BGNE shares have gain 8.12% over the last week, with a monthly amount drifted -2.87%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 26, February 2024, BeiGene Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates. In a post published today on Yahoo Finance, Continued rapid global growth with record total revenues of $634 million in fourth quarter and $2.5 billion in full-year 2023, increases of 67% and 74% from the prior-year periods.
From an analyst’s perspective:
Previously, Macquarie started tracking the stock with Outperform rating on September 12, 2023, and set its price target to $259. On August 17, 2023, Jefferies initiated with a Buy rating and assigned a price target of $287 on the stock. Citigroup started tracking the stock assigning a Buy rating and suggested a price target of $275 on July 17, 2023. Bernstein downgraded its rating to a Mkt Perform and reduced its price target to $196 on June 30, 2023. Daiwa Securities started tracking with a Buy rating for this stock on January 12, 2023, and assigned it a price target of $308. In a note dated October 13, 2022, SVB Leerink upgraded an Outperform rating on this stock and boosted its target price from $177 to $200.
BeiGene Ltd ADR [BGNE] stock has fluctuated between $132.95 and $272.49 over the past year. Currently, Wall Street analysts expect the stock to reach $200.5 within the next 12 months. BeiGene Ltd ADR [NASDAQ: BGNE] shares were valued at $160.26 at the most recent close of the market. An investor can expect a potential return of 25.11% based on the average BGNE price forecast.
Analyzing the BGNE fundamentals
BeiGene Ltd ADR [NASDAQ:BGNE] reported sales of 2.20B for the trailing twelve months, which represents a growth of 101.56%. Gross Profit Margin for this corporation currently stands at -0.03% with Operating Profit Margin at -0.22%, Pretax Profit Margin comes in at -0.24%, and Net Profit Margin reading is -0.51%. To continue investigating profitability, this company’s Return on Assets is posted at -1.53, Equity is -2.61 and Total Capital is -22.65. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -6.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 155.98 points at the first support level, and at 151.69 for the second support level. However, for the 1st resistance point, the stock is sitting at 163.33, and for the 2nd resistance point, it is at 166.39.
BeiGene Ltd ADR [BGNE] reported earnings per share of $2.01 for its fiscal quarter that ended on 9/29/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$3.11/share, meaning a difference of $5.12 and a surprise factor of 164.60%. By comparison, the stated earnings for the previous quarter ended on 6/29/2023 were -$3.64 per share as compared to estimates of -$2.81 per share, a difference of -$0.83 representing a surprise of -29.50%.
Ratios To Look Out For
For context, BeiGene Ltd ADR’s Current Ratio is 3.16. As well, the Quick Ratio is 2.91, while the Cash Ratio is 0.05. Considering the valuation of this stock, the price to sales ratio is 6.94, the price to book ratio is 4.13.
Transactions by insiders
Recent insider trading involved Lee Chan Henry, SVP, General Counsel, that happened on Jul 31 when 791.0 shares were sold. Chief Financial Officer, Wang Julia Aijun completed a deal on Jul 03 to sell 472.0 shares. Meanwhile, President, COO & GM China Wu Xiaobin sold 1495.0 shares on Jun 26.
